8-K: Larimar Therapeutics Advances Friedreich's Ataxia Drug

Larimar Therapeutics provides positive clinical data for nomlabofusp, targeting a Q2 2026 BLA submission for Friedreich's Ataxia.

Summary

• Larimar Therapeutics posted an updated corporate slide presentation on November 10, 2025, detailing progress on nomlabofusp (CTI-1601) for Friedreich's Ataxia (FA).
• Nomlabofusp is positioned as the first potential disease-modifying therapy designed to address the underlying frataxin (FXN) deficiency in FA.
• Initial 50 mg Open Label Study data showed 100% of participants with data at 6 months achieved skin FXN levels over 50% of median levels in healthy volunteers.
• The mFARS (modified Friedreich's Ataxia Rating Scale) median score improved by 2.25 in Open Label study participants after 1 year, compared to a median worsening of 1.00 in the FACOMS natural history reference population.
• Consistent directional improvements were observed after 1 year across four key clinical outcomes: mFARS, FARS-ADL, 9-HPT, and MFIS.
• Seven of 39 participants in the Open Label study (65 total across all nomlabofusp studies) experienced anaphylaxis, mostly on the initial day and within the first 6 weeks; all returned to health after standard treatment.
• Larimar is modifying its starting dose regimen to mitigate anaphylaxis risk, including antihistamines, a 5 mg test dose, and a gradual increase to 50 mg daily, with FDA agreement.
• The company continues to target a Biologics License Application (BLA) submission in Q2 2026, seeking accelerated approval based on increases in skin FXN levels.
• Larimar reported $175.4 million in cash and investments as of September 30, 2025, with a projected cash runway into Q4 2026.
• A global Phase 3 double-blind placebo-controlled study is being qualified across sites in the U.S., Europe, U.K., Canada, and Australia, targeting 100-150 ambulatory participants aged 2-40 years.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for nomlabofusp, demonstrating significant increases in FXN levels and improvements in clinical outcomes compared to natural disease progression. Regulatory clarity and FDA agreement on the modified dosing regimen, coupled with participation in the START Pilot Program, de-risk the development pathway. While anaphylaxis events are a negative, the proposed mitigation strategy has FDA backing. The financial runway is adequate for the near term, supporting continued development towards a BLA submission and potential launch.

Positives

• Nomlabofusp demonstrated significant increases in skin FXN levels, with 100% of participants in the Open Label study achieving levels over 50% of healthy volunteers by 6 months.
• Clinical outcomes showed a median mFARS score improvement of 2.25 after 1 year, contrasting with a worsening in the natural history population, suggesting potential clinical benefit.
• Consistent directional improvements were observed across multiple key clinical measures (mFARS, FARS-ADL, 9-HPT, MFIS).
• The FDA has agreed with Larimar's modified dosing regimen to mitigate anaphylaxis risk, providing regulatory clarity.
• Larimar is a participant in the FDA's START Pilot Program, indicating expedited clinical and regulatory development support for nomlabofusp.
• The company has a strong cash position of $175.4 million as of September 30, 2025, providing a projected cash runway into Q4 2026.
• Preclinical data consistently showed nomlabofusp's ability to extend survival, prevent ataxic gait, restore mitochondrial function, and preserve cardiac function in FA mouse models.
• Nomlabofusp has a granted composition of matter patent extending into 2040 and is eligible for 12 years of market exclusivity in the US and 10 years in the EU upon approval.

Negatives

• Seven out of 39 participants in the Open Label study experienced anaphylaxis, necessitating a modification of the starting dose regimen.
• The need for a modified dosing regimen and pre-treatment with antihistamines adds complexity to patient administration and monitoring.

Risks

• The success, cost, and timing of product development activities, nonclinical studies, and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA, are uncertain.
• Larimar's ability to timely implement the revised dosing regimen in its clinical program for nomlabofusp may face challenges.
• Preliminary clinical trial results may differ from final clinical trial results, and earlier non-clinical and clinical data may not be predictive of future outcomes.
• Delays in patient recruitment, potentially due to changes in clinical protocols and adverse events, could impact timelines.
• The FDA may not ultimately agree with Larimar's nomlabofusp development strategy or the use of skin FXN levels as a surrogate endpoint for accelerated approval.
• Public health crises could impact Larimar's future clinical trials, manufacturing, regulatory, nonclinical study timelines, operations, and general economic conditions.
• Larimar's ability and the ability of third-party manufacturers to optimize and scale nomlabofusp's manufacturing process may encounter difficulties.
• Obtaining regulatory approvals for nomlabofusp and future product candidates is not guaranteed.
• Developing sales and marketing capabilities, alone or with collaborators, and successfully commercializing any approved product candidates presents a challenge.
• Larimar's ability to raise the necessary capital to conduct its product development activities is a continuous risk.

Future Outlook

Larimar Therapeutics continues to target a Biologics License Application (BLA) submission for nomlabofusp in Q2 2026, seeking accelerated approval based on increases in skin frataxin (FXN) levels. The company anticipates a U.S. launch for nomlabofusp in early 2027. Ongoing clinical development includes expanding the Open Label study to adolescents and new participants, with plans to enroll children (2-11 years) directly into the study, and initiating a global Phase 3 study.

Management Comments

• "Based on these compelling data, we continue to target the BLA filing for Q2 2026 and believe that nomlabofusp could be the first disease modifying therapy for patients with FA."

Industry Context

Friedreich's Ataxia (FA) is a rare, progressive, and debilitating neurodegenerative disease affecting approximately 20,000 patients globally, with about 5,000 in the U.S. It is characterized by a genetic defect leading to reduced frataxin (FXN) levels, causing symptoms like unsteady posture, frequent falling, and eventual wheelchair confinement, with a life expectancy of 30-50 years. There is a significant unmet medical need, as the only currently approved treatment does not address the underlying frataxin deficiency. Nomlabofusp, if approved, would be the first disease-modifying therapy for FA, potentially transforming patient outcomes in a market with high unmet need.

Comparison to Industry Standards

• Nomlabofusp's median mFARS score improvement of 2.25 after 1 year in the Open Label study compares favorably to a median worsening of 1.00 observed in the FACOMS natural history reference population, indicating a potential clinical benefit relative to the natural progression of the disease.
• The achievement of skin FXN levels over 50% of median healthy volunteers in 100% of participants with data at 6 months is significant, as lower FXN levels are strongly correlated with earlier disease onset, faster progression, and shorter time to loss of ambulation, as shown in studies by Plasterer et al. and Rummey et al.
• The company's participation in the FDA's START Pilot Program, a new milestone-driven program designed to accelerate rare disease therapies, places nomlabofusp among a select group of 7 novel drug development programs receiving enhanced regulatory support, suggesting a high level of FDA interest and confidence in the program's potential.

Stakeholder Impact

• **Shareholders**: Positive clinical data and a clear regulatory path could increase investor confidence and potentially lead to share price appreciation. The cash runway provides stability for continued development.
• **Patients (Friedreich's Ataxia)**: Nomlabofusp offers the potential for the first disease-modifying therapy, which could significantly improve quality of life and extend life expectancy. The modified dosing regimen aims to enhance safety.
• **Employees**: Continued progress in clinical development and regulatory milestones provides job security and potential for growth within the company.
• **Regulatory Authorities (FDA, EMA)**: The company's proactive engagement and FDA agreement on the dosing strategy demonstrate a commitment to patient safety and regulatory compliance.

Next Steps

• Continue enrolling participants on the new starting dose regimen with long-term 50 mg dose in the Open Label study, including adolescents and those new to a nomlabofusp study.
• Continue introducing the lyophilized dosage form of nomlabofusp.
• Plan to enroll children (2-11 years of age) directly into the Open Label study.
• Provide an update on the Open Label study status and regulatory discussions in Q1 2026.
• Target BLA submission seeking accelerated approval in Q2 2026.
• Initiate the global Phase 3 double-blind placebo-controlled study with participants aged 12-40 years, expanding to 2-40 years when the dose is confirmed in children.

Key Dates

Recommendation

The filing presents compelling positive clinical data for nomlabofusp, demonstrating significant increases in frataxin levels and consistent improvements across multiple clinical outcomes compared to natural disease progression in Friedreich's Ataxia. The FDA's agreement on the modified dosing regimen and the inclusion in the START Pilot Program significantly de-risk the regulatory pathway towards accelerated approval. With a clear BLA submission target in Q2 2026 and a projected U.S. launch in early 2027, coupled with a solid cash runway into Q4 2026, Larimar Therapeutics is well-positioned to bring a potentially first-in-class disease-modifying therapy to a market with high unmet medical need. The potential for market exclusivity and strong IP further enhances its long-term value proposition, making it a strong buy for investors seeking exposure to innovative rare disease therapeutics.

Keywords

Friedreich's Ataxia, Nomlabofusp, CTI-1601, Frataxin, FXN, Rare Disease, Biologics License Application, BLA, Accelerated Approval, Clinical Trials, Orphan Drug, Biotechnology, Therapeutics, SEC Filing